Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -9.23%117.06B | -3.82%76.09B | 11.04%36.03B | 39.01%177.66B | 35.58%128.97B | 30.61%79.12B | 21.74%32.44B | -9.70%127.81B | -12.84%95.12B | -16.02%60.57B |
| Operating income | -9.23%117.06B | -3.82%76.09B | 11.04%36.03B | 39.01%177.66B | 35.58%128.97B | 30.61%79.12B | 21.74%32.44B | -9.70%127.81B | -12.84%95.12B | -16.02%60.57B |
| Operating expenses | 9.63%-102.75B | 5.92%-66.45B | -8.68%-31.67B | -40.72%-155.42B | -38.25%-113.7B | -34.76%-70.63B | -26.66%-29.14B | 7.90%-110.44B | 10.77%-82.24B | 14.36%-52.41B |
| Gross profit | -6.26%14.31B | 13.63%9.64B | 31.85%4.36B | 28.10%22.25B | 18.55%15.27B | 3.98%8.49B | -9.33%3.31B | -19.69%17.37B | -24.05%12.88B | -25.31%8.16B |
| Selling expenses | -5.96%-1.97B | -9.57%-1.3B | -6.82%-625.35M | -3.88%-2.63B | -3.75%-1.86B | -5.08%-1.19B | -5.47%-585.4M | -3.17%-2.53B | 2.82%-1.79B | 4.52%-1.13B |
| Administrative expenses | -0.78%-4.9B | 1.32%-3.24B | -17.61%-1.6B | -6.91%-6.96B | -9.80%-4.87B | -11.72%-3.28B | -2.13%-1.36B | 7.23%-6.51B | 14.31%-4.43B | 13.26%-2.94B |
| Research and development expenses | -4.78%-1.91B | -5.18%-1.18B | -1.63%-494.04M | -11.52%-2.71B | -8.43%-1.82B | -0.55%-1.13B | 10.25%-486.13M | 1.38%-2.43B | 1.91%-1.68B | -7.29%-1.12B |
| Profit from asset sales | -83.32%17.57M | 67.25%15.16M | -42.86%4.21M | 381.04%114.4M | 680.32%105.3M | -50.65%9.06M | 540.84%7.36M | -90.22%23.78M | 359.62%13.5M | 510.68%18.36M |
| Revaluation surplus | 102.59%5.79M | 97.49%-6.26M | 107.09%7.68M | -9.43%-669.04M | 73.53%-223.57M | 77.81%-249.76M | -23.98%-108.24M | 43.22%-611.39M | 48.66%-844.56M | -23.53%-1.13B |
| -Changes in the fair value of other assets | 102.59%5.79M | 97.49%-6.26M | 107.09%7.68M | -9.43%-669.04M | 73.53%-223.57M | 77.81%-249.76M | -23.98%-108.24M | 43.22%-611.39M | 48.66%-844.56M | -23.53%-1.13B |
| Impairment and provision | -218.76%-452.97M | 348.72%343.75M | -57.72%-25.83M | -35.34%-908.04M | 15.83%-142.1M | 156.77%76.61M | -298.67%-16.38M | 13.65%-670.92M | -11.90%-168.84M | 24.65%-134.95M |
| -Other impairment is provision | -218.76%-452.97M | 348.72%343.75M | -57.72%-25.83M | -35.34%-908.04M | 15.83%-142.1M | 156.77%76.61M | -298.67%-16.38M | 13.65%-670.92M | -11.90%-168.84M | 24.65%-134.95M |
| Special items of operating profit | -13.66%335.6M | -51.97%155.97M | 232.12%98.14M | -65.38%81.79M | 256.35%388.72M | 9.09%324.71M | -122.81%-74.28M | 534.24%236.22M | -270.60%-248.61M | -19.69%297.67M |
| Adjustment items of operating profit | ---- | -348.72%-687.51M | ---- | ---- | ---- | ---153.21M | ---- | ---- | ---- | ---- |
| Operating profit | -22.40%5B | 30.54%3.44B | 181.40%1.58B | 82.49%7.92B | 92.37%6.45B | 48.56%2.64B | -58.02%560.29M | -42.01%4.34B | -45.62%3.35B | -59.06%1.78B |
| Financing cost | 43.32%-1.26B | -20.02%-627.63M | -132.51%-356.46M | 9.42%-1.36B | -175.76%-2.23B | -299.24%-522.94M | 69.89%-153.31M | -6,506.82%-1.51B | -231.24%-807.34M | -213.39%-130.99M |
| Adjustment items of earning before tax | -156.21%-37.19M | -118.53%-18.6M | -84.75%13.2M | 1,772.24%42.35M | 428.13%66.16M | 1,348.07%100.38M | 4,199.16%86.54M | 100.40%2.26M | 102.29%12.53M | -84.45%6.93M |
| Earning before tax | -13.59%3.7B | 26.27%2.8B | 149.92%1.23B | 132.70%6.6B | 67.67%4.29B | 34.13%2.22B | -40.36%493.52M | -59.15%2.83B | -58.98%2.56B | -63.27%1.65B |
| Tax | 16.10%-1.31B | -25.97%-1.03B | -86.37%-513.64M | -147.23%-2.4B | -41.18%-1.56B | -24.08%-820.93M | 21.29%-275.6M | 58.45%-970.8M | 45.76%-1.1B | 47.66%-661.59M |
| After-tax profit from continuing operations | -12.15%2.39B | 26.45%1.76B | 230.29%719.75M | 126.37%4.2B | 99.61%2.73B | 54.18%1.39B | -40.67%217.92M | -61.94%1.85B | -68.88%1.37B | -72.88%904.76M |
| After-tax profit from non-continuing business | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 103.78%10.12M | 143.80%85.62M | 183.52%85.62M |
| Earning after tax | -12.15%2.39B | 26.45%1.76B | 230.29%719.75M | 125.14%4.2B | 87.83%2.73B | 40.85%1.39B | -54.36%217.92M | -59.50%1.86B | -65.39%1.45B | -69.38%990.38M |
| Minority profit | -7.68%829.24M | -8.20%485.78M | 31.03%175.95M | -15.21%1.22B | -6.03%898.19M | -10.59%529.15M | -57.67%134.28M | 4.36%1.44B | -11.20%955.83M | -14.92%591.83M |
| Profit attributable to shareholders | -14.35%1.57B | 47.63%1.28B | 550.21%543.8M | 605.60%2.97B | 268.87%1.83B | 117.23%865.78M | -47.79%83.64M | -86.91%421.25M | -84.10%495.58M | -84.30%398.56M |
| Basic earnings per share | -16.50%0.2803 | 43.75%0.23 | 670.63%0.0971 | 657.14%0.53 | 304.46%0.3357 | 128.57%0.16 | -52.81%0.0126 | -88.14%0.07 | -85.46%0.083 | -85.11%0.07 |
| Diluted earnings per share | -15.54%0.2793 | 53.33%0.23 | 670.63%0.0971 | 960.00%0.53 | 340.35%0.3307 | 114.29%0.15 | -52.81%0.0126 | -91.23%0.05 | -86.68%0.0751 | -84.78%0.07 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership) | -- | -- | -- | PwC Zhongtian Certified Public Accountants LLP | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.